Jiangsu Aidea Pharmaceutical Co.Ltd(688488)
Independent directors’ comments on the 21st Meeting of the first board of directors of the company
Prior approval opinions on relevant matters
As an independent director of Jiangsu Aidea Pharmaceutical Co.Ltd(688488) (hereinafter referred to as the “company”), in accordance with the guiding opinions on the establishment of independent director system in listed companies, the stock listing rules of Shanghai Stock Exchange, the articles of association and other relevant provisions, in the attitude of being responsible to the company and all shareholders, and based on an independent, prudent and objective position, The company has conducted a pre audit on the following matters to be considered at the 21st Meeting of the first board of directors, and issued the following pre approval opinions:
1、 Prior approval opinions on the proposal on the estimation of daily connected transaction quota of the company in 2022
The estimated amount of the company’s daily related party transactions in 2022 is based on the daily business behavior of the company’s actual production and operation needs, based on the market price and following the principle of fair and reasonable pricing, without damaging the interests of the company, its subsidiaries and shareholders. Such related party transactions will not adversely affect the company’s independent operation, financial status and operating results, and the company will not rely on related parties for such transactions.
Therefore, we agree to submit the proposal to the 21st Meeting of the first board of directors of the company for deliberation. Related directors should avoid voting when considering the proposal.
(no text below)
